Indian CDMO investing $55 million in expanding APIs production

Piramal Pharma Solutions (PPS), the contract development and manufacturing (CDMO) arm of India’s Piramal Enterprises (BSE: 500302), says it plans to invest $55 million across its sites in North America and Asia, to expand its active pharmaceutical ingredients (API) manufacturing capabilities and capacities.

A part of this investment will go into new state-of-the-art, multi-purpose plants, with over 270kL of total capacity, to support the current pipeline of approximately 80 late-stage programs that PPS is currently assisting its partners with at various global sites. PPS will also expand its potency footprint (new Occupational Exposure Limit: ≥10 ng/m3) at its plant in Riverview, Michigan, while augmenting early development capabilities out of Ennore, India, through additions of GMP kilo labs and a pilot plant. To serve its European biotech customers better, PPS will add early development capabilities in both, drug substance and drug product, out of its Morpeth, UK, facility. Support functions such as Analytical capabilities, R&D infrastructure, automation, and IT systems will also be expanded at all API sites through this investment.

Adds to previous investments and acquisition